Influence of different pretherapeutic parameters on OS and EFS in patients undergoing first-line treatment (data available for 227 patients)
| . | Number evaluable . | OS . | RR (OS) . | EFS . | RR (EFS) . |
|---|---|---|---|---|---|
| Age | 225 | 0.103 | 0.013 | 1.20* | |
| WBC | 177 | 0.793 | 0.323 | ||
| Blast count in BM | 146 | 0.232 | 0.228 | ||
| CD34+ | 120 | 0.217 | 0.297 | ||
| FLT3-LM | 227 | 0.010 | 4.12 | 0.013 | 1.69 |
| FLT3-TKD | 223 | 0.540 | 0.733 | ||
| FAB subtype | 213 | 0.366 | 0.346 | ||
| Chromosomal aberrations | 224 | 0.341 | 0.626 | ||
| NPM1 mutation type | 227 | 0.842 | 0.283 | ||
| Initial NPM1 level | 227 | 0.915 | 0.222 |
| . | Number evaluable . | OS . | RR (OS) . | EFS . | RR (EFS) . |
|---|---|---|---|---|---|
| Age | 225 | 0.103 | 0.013 | 1.20* | |
| WBC | 177 | 0.793 | 0.323 | ||
| Blast count in BM | 146 | 0.232 | 0.228 | ||
| CD34+ | 120 | 0.217 | 0.297 | ||
| FLT3-LM | 227 | 0.010 | 4.12 | 0.013 | 1.69 |
| FLT3-TKD | 223 | 0.540 | 0.733 | ||
| FAB subtype | 213 | 0.366 | 0.346 | ||
| Chromosomal aberrations | 224 | 0.341 | 0.626 | ||
| NPM1 mutation type | 227 | 0.842 | 0.283 | ||
| Initial NPM1 level | 227 | 0.915 | 0.222 |
Significant parameters are presented in bold type.
BM indicates bone marrow, EFS, event-free survival; FAB, French-American-British; OS, overall survival; RR, relative risk; and WBC, white blood cell count.
For 10-year intervals.